Your browser doesn't support javascript.
loading
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.
Jerusalem, G; Farah, S; Courtois, A; Chirgwin, J; Aebi, S; Karlsson, P; Neven, P; Hitre, E; Graas, M P; Simoncini, E; Abdi, E; Kamby, C; Thompson, A; Loibl, S; Gavilá, J; Kuroi, K; Marth, C; Müller, B; O'Reilly, S; Gombos, A; Ruhstaller, T; Burstein, H J; Rabaglio, M; Ruepp, B; Ribi, K; Viale, G; Gelber, R D; Coates, A S; Loi, S; Goldhirsch, A; Regan, M M; Colleoni, M.
Affiliation
  • Jerusalem G; International Breast Cancer Study Group, Bern, Switzerland; Medical Oncology Department, CHU Liège, Liège University, Liège, Belgium. Electronic address: g.jerusalem@chuliege.be.
  • Farah S; International Breast Cancer Study Group Statistical Center, Division of Biostatistics, Dana-Farber Cancer Institute, Boston, USA.
  • Courtois A; Medical Oncology Department, CHU Liège, Liège University, Liège, Belgium.
  • Chirgwin J; Breast Cancer Trials-Australia and New Zealand, University of Newcastle, Callaghan, Australia; Box Hill and Maroondah Hospitals, Monash University, Clayton, Australia.
  • Aebi S; Division of Medical Oncology, Cancer Center, Lucerne Cantonal Hospital, Lucerne, Switzerland; Faculty of Medicine, University of Bern, Bern, Switzerland.
  • Karlsson P; Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Neven P; Gynecologic Oncology and Multidisciplinary Breast Center, University Hospitals UZ-Leuven, KU Leuven, Leuven, Belgium.
  • Hitre E; Department of Medical Oncology and Clinical Pharmacology "B", National Institute of Oncology, Budapest, Hungary.
  • Graas MP; Montlégia Hospital, Liège, Belgium.
  • Simoncini E; ASST Spedali Civili di Brescia, Brescia, Italy.
  • Abdi E; The Tweed Hospital, Griffith University Gold Coast, Tweed Heads, Australia.
  • Kamby C; Danish Breast Cancer Group and Rigshospitalet, Copenhagen, Denmark.
  • Thompson A; Scottish Cancer Trials Breast Group and Division of Surgical Oncology, Baylor College of Medicine, Houston, USA.
  • Loibl S; German Breast Group Forschungs GmbH, Neu-Isenburg, Germany.
  • Gavilá J; SOLTI Group and Fundación Instituto Valenciano de Oncologia, Valencia, Spain.
  • Kuroi K; Japan Breast Cancer Research Group and Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
  • Marth C; Austrian Breast & Colorectal Cancer Study Group and Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria.
  • Müller B; Chilean Cooperative Group for Oncologic Research (GOCCHI), Providencia, Santiago, Chile.
  • O'Reilly S; Cancer Trials Ireland, Dublin, Ireland; University College Cork, Cork University Hospital, Cork, Ireland.
  • Gombos A; Université Libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium.
  • Ruhstaller T; International Breast Cancer Study Group, Bern, Switzerland; Swiss Group for Clinical Cancer Research SAKK, Bern, Switzerland; Breast Center St. Gallen, St. Gallen, Switzerland; Faculty of Medicine, University of Basel, Basel, Switzerland.
  • Burstein HJ; Medical Oncology Department, CHU Liège, Liège University, Liège, Belgium; Harvard Medical School, Boston, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
  • Rabaglio M; International Breast Cancer Study Group, Bern, Switzerland; Swiss Group for Clinical Cancer Research SAKK, Bern, Switzerland; Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Ruepp B; International Breast Cancer Study Group, Bern, Switzerland.
  • Ribi K; International Breast Cancer Study Group, Bern, Switzerland.
  • Viale G; Department of Pathology, University of Milan, Milan, Italy; IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Gelber RD; International Breast Cancer Study Group Statistical Center, Division of Biostatistics, Dana-Farber Cancer Institute, Boston, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Harvard TH Chan School of Public Health, Boston, USA; Frontier Science Foundation, Boston, USA.
  • Coates AS; International Breast Cancer Study Group, Bern, Switzerland; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
  • Loi S; International Breast Cancer Study Group, Bern, Switzerland; Peter MacCallum Cancer Center, University of Melbourne, Melbourne, Australia.
  • Goldhirsch A; International Breast Cancer Study Group, Bern, Switzerland; IEO European Institute of Oncology, IRCCS, Milan, Italy.
  • Regan MM; International Breast Cancer Study Group Statistical Center, Division of Biostatistics, Dana-Farber Cancer Institute, Boston, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
  • Colleoni M; International Breast Cancer Study Group, Bern, Switzerland; Division of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Ann Oncol ; 32(10): 1256-1266, 2021 10.
Article in En | MEDLINE | ID: mdl-34384882
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Type of study: Clinical_trials Aspects: Patient_preference Limits: Female / Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2021 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Type of study: Clinical_trials Aspects: Patient_preference Limits: Female / Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2021 Document type: Article